In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on TrovaGene (TROV), with a price target of $3. The company’s shares opened today at $0.73, close to its 52-week low of $0.65.
“Trovagene is presenting data from its ongoing P1b/2 study of Onvansertib (a polo-like kinase inhibitor, PLK inhibitor) in combination with low-dose cytarabine (LDAC) or decitabine in acute myeloid leukemia (AML) tonight at ASH.”
According to TipRanks.com, McCarthy is a 2-star analyst with an average return of 0.3% and a 37.7% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
TrovaGene has an analyst consensus of Moderate Buy, with a price target consensus of $2.75.
Based on TrovaGene’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $3.77 million. In comparison, last year the company had a GAAP net loss of $4.29 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Trovagene, Inc. is a clinical-stage, precision medicine oncology therapeutics company. Its focuses on developing PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor.